AVIENT CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AVIENT CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $3.84B | Feb 13, 2015 |
| FY2014 | Dec 31, 2013 | $3.77B | Feb 13, 2015 |
| FY2014 | Dec 31, 2012 | $2.86B | Feb 13, 2015 |
| FY2013 | Dec 31, 2011 | $2.71B | Feb 13, 2014 |
| FY2012 | Dec 31, 2010 | $2.62B | Feb 12, 2013 |
| FY2011 | Dec 31, 2009 | $2.06B | Feb 17, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.26B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.24B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $3.14B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.40B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $3.32B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $997.00M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $924.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $609.10M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $711.50M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $658.60M | Feb 25, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $892.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $882.70M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $943.80M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $252.90M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $210.20M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $149.70M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $171.50M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $153.30M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $169.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $75.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $703.10M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $230.80M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $74.30M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $1.70M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $22.80M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $32.80M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $465.30M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $329.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $196.80M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $243.30M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $279.70M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $65.00M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $33.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $38.00M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $52.80M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $20.50M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $98.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $90.30M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $84.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $83.20M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $59.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $50.60M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $49.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $45.30M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $50.40M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $812.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $727.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $695.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $639.40M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $664.10M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $548.40M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $500.40M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $446.20M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $423.30M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $408.70M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $256.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $201.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $398.40M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $233.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $221.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $300.80M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $253.70M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $202.40M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $227.60M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $121.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $119.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $105.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $100.60M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $63.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $81.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $76.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $79.60M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $84.20M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.03B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.81B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.97B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $6.09B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $5.00B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.87B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.27B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.72B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $2.71B | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $2.74B | Feb 19, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.31B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.32B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.33B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.77B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.70B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.05B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $540.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $598.50M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $724.70M | Feb 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.66B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.72B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.67B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.28B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.31B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $685.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $639.10M | Feb 25, 2021 |
| FY2018 | May 31, 2018 | $41.50M | Feb 19, 2019 |
| FY2019 | Dec 31, 2017 | $599.30M | Feb 19, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.88B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.81B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.82B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.21B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.06B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.00B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $472.90M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $387.10M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $491.20M | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $170.90M | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $243.60M | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $226.70M | Feb 19, 2019 |
| FY2018 | Dec 31, 2015 | $279.80M | Feb 19, 2019 |
| FY2016 | Dec 31, 2014 | $238.60M | Feb 16, 2017 |
| FY2016 | Dec 31, 2013 | $365.20M | Feb 16, 2017 |
| FY2015 | Dec 31, 2012 | $210.00M | Feb 12, 2016 |
| FY2014 | Dec 31, 2011 | $191.90M | Feb 13, 2015 |
| FY2013 | Dec 31, 2010 | $378.10M | Feb 13, 2014 |
| FY2012 | Dec 31, 2009 | $222.70M | Feb 12, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.92B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.07B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.08B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.18B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.86B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.87B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.23B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.36B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.31B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.26B | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 6 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 6 | Feb 25, 2021 |